PACIRA BIOSCIENCES, INC. Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax
PACIRA BIOSCIENCES, INC. (PCRX) had Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax of $0 as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $1.00K.
- 2025-12-31: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $40.00K.
- 2025-09-30: Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax $26.00K.
| Period end | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-04 |
| 2026-03-31 | $1.00K 10-Q · filed 2026-04-30 |
| 2025-12-31 | $40.00K 10-Q · filed 2026-08-04 |
| 2025-09-30 | $26.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $9.00K 10-Q · filed 2025-08-05 |
| 2025-03-31 | $73.00K 10-Q · filed 2025-05-08 |
| 2024-12-31 | $209.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $465.00K 10-Q · filed 2024-11-06 |
| 2024-06-30 | $9.00K 10-Q · filed 2024-07-30 |
| 2024-03-31 | $28.00K 10-Q · filed 2024-05-07 |
| 2023-12-31 | $111.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $1.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 |
| 2023-03-31 | $18.00K 10-Q · filed 2023-05-03 |
| 2022-12-31 | $25.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-03 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 |
| 2021-12-31 | $182.00K 10-Q · filed 2022-11-03 |
| 2021-09-30 | $109.00K 10-Q · filed 2021-11-03 |
| 2021-06-30 | $137.00K 10-Q · filed 2021-08-03 |
| 2021-03-31 | $155.00K 10-Q · filed 2021-05-04 |
| 2020-12-31 | $350.00K 10-K · filed 2022-02-28 |
| 2020-09-30 | $858.00K 10-Q · filed 2020-10-30 |
| 2020-06-30 | $1.49M 10-Q · filed 2020-08-06 |
| 2019-12-31 | $346.00K 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |